Mark Pennesi

Scientific Advisor at Ocugen

Dr. Pennesi is an Associate Professor of Ophthalmology at the Oregon Health & Science University (OHSU) School of Medicine and Division Chief of the Ophthalmic Genetics Service at the OHSU Casey Eye Institute.

Since joining the OHSU faculty, Dr. Pennesi has been a principal investigator on many first-in-human clinical trials including for: LCA Type II and Type 10, Usher Syndrome Type IB and 2A, Stargardt disease, X-linked Retinoschisis, X-Linked retinitis pigmentosa and achromatopsia.

Dr. Pennesi pursued combined at MD/PhD at Baylor College of Medicine in Houston, Texas and residency in Ophthalmology at University of California – San Francisco, followed by an Ophthalmic Genetics Fellowship at Casey Eye Institute.

Location

Dallas, United States

Links


Org chart

This person is not in the org chart


Teams


Offices

This person is not in any offices


Ocugen

1 followers

Ocugen Inc. (NASDAQ: OCGN) is a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to fight COVID-19.


Industries

Employees

51-200

Links